Biomarkers of immune-related adverse events for zoning pathophysiology and exploring novel markers

Biomarkers of Immune-related adverse events for Zoning pathophysiology and Exploring Novel markers - BIZEN-M study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000056902

Enrollment

200

Registered

2025-02-03

Start date

2025-02-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with a history of immune checkpoint inhibitor treatment

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients after immune checkpoint inhibitor administration

Exclusion criteria

Exclusion criteria: Women who are pregnant or may be pregnant

Design outcomes

Primary

Measure	Time frame
We will perform the MUSCAT Assay using plasma from patients who developed irAE and those treated with immune checkpoint inhibitors without irAE, and compare the results of anti-cancer antigen antibodies and autoantibodies.	—

Countries

Japan

Contacts

Public ContactMasaya Iwamuro

Okayama University Hospital Department of Gastroenterology

iwamuromasaya@yahoo.co.jp0862357219

Outcome results